AIMS: Both biodegradable polymer @entity3446 -eluting stents and permanent polymer @entity2239 -eluting stents offer potential for enhanced late outcomes in comparison with earlier-generation permanent polymer @entity3446 -eluting stents. However, long-term comparative efficacy data among these devices remain a scientific gap. We aimed to compare the efficacy and safety of biodegradable polymer @entity3446 -eluting stents (Yukon Choice PC) versus permanent polymer everolimus-eluting stents (XIENCE) versus permanent polymer @entity3446 -eluting stents ( @entity20204 ) at five-year follow-up. METHODS AND RESULTS: Overall, 2,603 @entity1 were randomised to treatment with the Yukon Choice PC (n=1,299), XIENCE (n=652) or @entity20204 (n=652) stents. The primary endpoint was the device-oriented composite of @entity204 , target vessel-related @entity583 ( @entity583 ), or @entity75 revascularisation (TLR). The main secondary endpoint was definite/probable @entity715 ( @entity715 ). Follow-up was performed up to five years. Concerning the primary endpoint, there was no significant difference between Yukon Choice PC and XIENCE stents (20.5% vs. 19.5%, HR=1.04, 95% CI: 0.84-1.29; p=0.71) or between @entity20204 and XIENCE stents (23.5% vs. 19.5%, HR=1.21, 95% CI: 0.95-1.53; p=0.12). In terms of safety, rates of @entity715 were similar with both Yukon Choice PC and XIENCE (1.2% vs. 1.4%; HR=0.83, 95% CI: 0.37-1.91; p=0.67) but numerically higher with @entity20204 as compared to XIENCE (2.4% vs. 1.4%, HR=1.67, 95% CI: 0.73-3.82; p=0.22). CONCLUSIONS: Biodegradable polymer Yukon Choice PC and permanent polymer XIENCE stents showed comparable clinical outcomes at five years. Permanent polymer @entity20204 stents showed numerically higher rates of device-related adverse events.

Five-year outcomes from a trial of three limus-eluting stents with different polymer coatings in XXXX with coronary artery disease: final results from the ISAR-TEST 4 randomised trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity75 :: ('MESH:D001927', 'Disease') :: ['target lesion'] @entity3446 :: ('MESH:D020123', 'Chemical') :: ['sirolimus'] @entity2239 :: ('MESH:C107135', 'Chemical') :: ['everolimus'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI'] @entity204 :: ('MESH:D003643', 'Disease') :: ['cardiac death'] @entity715 :: ('MESH:D013927', 'Disease') :: ['ST', 'stent thrombosis'] @entity20204 :: ('11155', 'Gene') :: ['CYPHER']
@entity1 :: (9606,Species) :: ['patients']
